Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

14-3-3 η (Eta) Protein as a Marker of Disease Activity, Severity and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis.

NCT04937140 is registered in ClinicalTrials.gov with Sohag University as lead sponsor.

NCT NCT04937140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04937140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
14-3-3 η (Eta) Protein as a Marker of Disease Activity, Severity and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis.
Lead sponsor
Sohag University
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2021
Completion date
September 30, 2022
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis